Showing 1,523 results

Filters Content type: News, Editors' picks Topic: Pharmaceutical industry

News and information on drug companies, the cost of therapies, patent protections and generic medicines.

New & experimental hepatitis C treatment

Gilead to seek okay for combo hepatitis C pill in first quarter

Editor's pick
Reuters
18 December 2013
New & experimental hepatitis C treatment

Gilead Announces SVR12 Rates From Three Phase 3 Studies Evaluating a Once-Daily Fixed-Dose Combination of Sofosbuvir and Ledipasvir for Genotype 1 Hepatitis C Patients

Editor's pick
Gilead press release
18 December 2013
New & experimental hepatitis C treatment

Analysis: Fight for cheap drugs shifts from AIDS to new hepatitis pills

Editor's pick
Reuters
16 December 2013
Changing treatment

U.S. FDA Approves Gilead’s Once-Daily Single Tablet HIV-1 Regimen Complera® for Patients Switching from a Stable Regimen

Editor's pick
Gilead press release
16 December 2013
Access to healthcare

US: Group Says Plans Discourage HIV Patients

Editor's pick
Wall Street Journal
12 December 2013
Pharmaceutical industry

Bristol-Myers Squibb adds medicine to patent pool for AIDS drugs

Editor's pick
Reuters
12 December 2013
New & experimental hepatitis C treatment

Why Talk Of A Hepatitis C Price War Should Act As A Warning To The Pharma Industry-At-Large

Editor's pick
Forbes
11 December 2013
New & experimental hepatitis C treatment

Express Scripts Pushes Price Competition for Gilead Drug

Editor's pick
Bloomberg
11 December 2013
Pharmaceutical industry

Activists Condemn Gilead for Exorbitant Price of Their New Hepatitis C Drug

Editor's pick
Fair Pricing Coalition / The Body
10 December 2013
Pharmaceutical industry

Fair Pricing Coalition Disappointed by the High Price of New Janssen Hepatitis C Drug Olysio (simeprevir)

Editor's pick
Fair Pricing Coalition
29 November 2013
Access to healthcare

Indian health activists move to prevent Gilead’s drug patent

Editor's pick
Financial Times
26 November 2013
Pharmaceutical industry

Hardly accessible Atripla in Eastern Europe & Central Asia

Editor's pick
EATG / EECA CAB
22 November 2013
New & experimental hepatitis C treatment

How Much? A Battle Over The Cost Of The New Hepatitis C Drugs

Editor's pick
Pharmalot
12 November 2013
Types of HIV tests

OraSure reports earnings, third-quarter loss of $1.9 million

Editor's pick
The Morning Call
7 November 2013
Clinical trials

Randomized clinical trials: 1 in 3 not reported

Editor's pick
Medscape (requires free registration)
4 November 2013
New & experimental HIV treatments

Dolutegravir matches or surpasses other regimens for first-line HIV treatment

News
30 October 2013
New & experimental HIV treatments

Janssen seeks European marketing approval for combination of once-daily darunavir with cobicistat

Editor's pick
News Medical Net
15 October 2013
Pharmaceutical industry

TAC debunks pharma’s myths around patent law reform

Editor's pick
Fix the Patent Laws
14 October 2013
New & experimental hepatitis C treatment

Idenix Shares Fall as J&J Buys Rival Hepatitis C Therapy

Editor's pick
Bloomberg
8 October 2013
New & experimental hepatitis C treatment

Investigational interferon-free regimen demonstrates undetectable hepatitis C virus in all patients reaching end of treatment in ongoing Phase II trial

Editor's pick
Boehringer-Ingelheim press release
8 October 2013
New & experimental hepatitis C treatment

Janssen Acquires Investigational NS5A Inhibitor for the Treatment of Hepatitis C from GlaxoSmithKline

Editor's pick
Janssen press release
8 October 2013
PrEP

PATH Evaluates Janssen’s Rilpivirine as HIV Infection Prophylactic

Editor's pick
Genetic Engineering & Biotechnology News
25 September 2013
Pharmaceutical industry

U.S. Government Shutdown Could Postpone FDA Advisory Panels

Editor's pick
The Street
25 September 2013
Pharmaceutical industry

Seven Ways to Speed up the HIV Treatment Pipeline

Editor's pick
Positive Lite
24 September 2013